This article discusses a study on the use of liver transplantation as a treatment option for patients with advanced hepatocellular carcinoma (HCC) after successful downstaging with lenvatinib, transcatheter arterial chemoembolization (TACE), and camrelizumab. The study found that three patients who underwent liver transplantation had positive outcomes with stable graft function, no tumor recurrence or metastasis, and promising results. The article highlights the potential benefits of combination therapy and calls for further research to provide more evidence. The document also provides supplementary material and author contributions for the study, which was funded by the National Natural Science Foundation of China and the Key Research and Development Program of Sichuan Province. The authors disclose potential conflicts of interest related to grant support and lecture fees from pharmaceutical companies. The data supporting the study's findings are available upon request from the corresponding author. [Extracted from the article]